Jump to Navigation

ICON studie

Titel: A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd): ICON study

 

 

Principal Investigator AMC: Jurgen Wegman, Man Wai Tang